About this trial
This is a comparative interventional study to determine the best way to prevent G-CSF induced bone pain in patients with hematological malignancies (blood cancers). G-CSF (Granulocyte Colony-Stimulating Factor) is a drug commonly used in these patients to boost white blood cell production, but it frequently causes severe bone pain.
The study is comparing two oral medications for their effectiveness as a preventive treatment:
* Diosmin-Hesperidin (a flavonoid supplement). * Loratadine (a common anti-allergy medication).
The core question the study is trying to answer is:
* Is diosmin-hesperidin effective in preventing G-CSF-induced bone pain compared to loratadine? * Does the combination of diosmin-hesperidin and loratadine offer better pain prevention than either drug alone?
Eligibility criteria
Qualifiers
Adults 18 to 65 years old
Patients with or without bone pain associated with G-CSF administration.
Willingness to provide informed consent to participate in the study.
Disqualifiers
Patients with solid tumors.
Pregnant or breastfeeding women.
Patients with known allergies or hypersensitivity to Loratadine, Diosmin- Hespiridin or Filgrastim.
Patients with pre-existing bone disorders or receiving bone modifying agents
Trial design
Treatments tested in this trial
- Loratadine
- Diosmin-Hesperidin
- Loratadine + Diosmin-Hesperidin